Inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory treatment in subjects with asthma and COPD. This review evaluates the role of nebulizers as an alternative to inhalers for delivering ICSs in asthma and COPD. I selected 16 randomized, placebo-controlled, blinded, longterm studies, mostly carried out in asthma (n ‫؍‬ 14) and COPD. Nebulized budesonide has been demonstrated to be effective and safe in children ages 1-8 years, and, with less evidence, in infants and adults with asthma. Other investigations, with the addition of in vitro and in vivo comparison studies, have shown that nebulized beclomethasone, fluticasone, and flunisolide are effective alternatives to nebulized budesonide in asthma and COPD. Efficient delivery of nebulized ICSs requires that the nebulizer system, the nebulized drug formulation, and the inhaling subject interact properly. The practices of mixing nebulized ICSs with bronchodilators and using nebulized ICSs in acute settings are promising, but require further confirmations, and at present cannot be recommended. I conclude that nebulizers may be considered as an effective alternative to inhalers for delivering ICSs and can be recommended to asthmatic and COPD subjects who are unwilling or unable to use inhalers. Newer formulations could possibly offer a relevant advance for a more efficient nebulization of ICSs.
Introduction
Inhaled corticosteroids (ICSs) are commonly used for aerosolization. Long-term regular use of ICSs is the mainstay of anti-inflammatory management in chronic persistent asthma of infants, children, and adults, throughout the severity. [1] [2] [3] ICSs are also administered to pre-schoolers with intermittent wheezing, but with less evidence of clinical efficacy. [4] [5] [6] [7] [8] Even if the therapeutic effect is more modest than in asthma, regular use of an ICS in combination with an inhaled long-acting ␤ agonist is increasingly uti-lized for the treatment of severe COPD with a history of repeated bronchitic exacerbations. [9] [10] [11] The role of ICSs in acute asthma and COPD is promising, 12 but not fully evidence-based. 13 The production of therapeutic aerosols requires specific delivery devices such as inhalers and nebulizers. Current guidelines for asthma. 1, 2 and COPD management, 14, 15 as well as for nebulized 16, 17 and aerosol therapy, 13 do not provide sufficient, specific guidance on the selection of the most appropriate device in different clinical settings. So, according to local habits and availability, there is tremendous variability among countries in the diffusion of different devices for administering an aerosol therapy. 18, 19 In more than 70 countries worldwide, ICSs are approved and utilized for nebulization in both children and adults, for asthma and COPD. Sometimes, such as in Italy, the use of nebulized ICSs is widespread 20 and critically discussed. 21 In many other countries ICSs are usually or exclusively delivered using hand-held inhalers; in the United States, budesonide is the only marketed nebulized ICS and approved for children ages 1-8 years with asthma by the FDA in August 2000. The availability of an effective nebulized ICS has been welcomed by U.S. clinicians 22 and is increasingly used. 23 Previously, alternative types of ICSs, such as nasal or parenteral formulations, had been proposed 24, 25 and used for the treatment of asthma. 26, 27 Four corticosteroids are currently marketed for nebulization: nebulized budesonide (BUD), beclomethasone dipropionate (BDP), flunisolide (FLU), and fluticasone propionate (FP). They are available as unit-dose vials of 2 mL; BUD, FP, and FLU are available as multiple strength formulations. All these drugs are well known for their high affinity to the glucocorticoid receptor, good topical antiinflammatory activity, and low tendency for systemic effects. [28] [29] [30] [31] The composition and some properties of the proprietary nebulized ICSs are reported in Appendix 1 in the supplementary materials at http://www.rcjournal.com. Poor water solubility is possibly the most relevant characteristic of the currently marketed formulations, which are available as suspensions, with some inherent drawbacks. [32] [33] [34] Some novel varieties of nebulized ICS are being developed. They are obtained by adding solubilization enhancers with the production of nano-suspensions and solutions, or embodying the drug in micellar systems with the manufacturing of nano-emulsions and liposomal fluids. 35 These newer formulations seem to be safe and stable, assure that more drug is generated as aerosol by the nebulizer, and have improved particle size distribution, 33, [36] [37] [38] [39] leading to higher drug doses to the lungs [40] [41] [42] and improved pharmacodynamics. 43, 44 The aim of this review is to evaluate whether nebulization may be considered as a useful alternative to inhalers for administering ICSs in asthma and COPD.
In Vitro Studies
In vitro investigations allow for important observations on aerosol behavior and contribute to cover some uncertainties due to the lack of extensive in vivo studies. In the supplementary Appendices 2 and 3 I have displayed the in vitro experiments with the marketed formulations of nebulized ICSs. 33,36 -39,45-69 To the aim of giving more homogeneous results, we have selected those studies reporting the inhaled mass (IM) as the relevant parameter of drug output, and the mass median aerodynamic diameter (MMAD), the geometric standard deviation, and the respirable fraction by cascade impaction as indices of aerosol granulometry. Once careful attention is paid to standardizing the environmental conditions, [70] [71] [72] [73] cascade impaction methods are the most accurate means of studying aerodynamic properties of suspensions such as ICSs.
Overall, jet nebulizers are the preferred system for nebulizing ICSs. Several in vitro studies with BUD [35] [36] 47, [74] [75] [76] and FLU 77 have shown a poor efficiency of conventional ultrasonic nebulizers for administering ICSs. Likewise, although mesh nebulizers offer promising results, 36, [38] [39] 49, 51, [53] [54] [55] [56] 67, 78 they have a higher purchase cost than jet systems. Moreover, maintenance may be difficult, as repeated nebulizations with suspensions seem to predispose to clogging and blockage of mesh holes. 79 Recently Berg and Picard 68 evaluated 30 commonly used jet nebulizer/compressor systems to nebulize BUD. Mimicking the breathing pattern of a child, the IM of studied aerosols ranged from 4% to 20% of initial drug charge (and from 1% to 9%, simulating the infant's breathing pattern). 68 These findings are also in substantial accordance with most studies, shown in the supplementary Appendix 4, 76, [80] [81] [82] [83] [84] [85] [86] [87] where the IM was evaluated using inhaling subjects and not a breathing simulator. The MMAD of studied aerosols ranged from 4.8 to 9.9 m. 68 It means that not all the studied systems seem to be suitable for nebulizing ICSs, because it is accepted that the probability of being delivered to the lungs is relevant only when the drug is contained in nebulized particles smaller than 5 m. 16 Likewise, not only nebulizer systems producing aerosols with MMAD Ͼ 5 m, but even those with MMAD of 2-3 m are not suitable for efficient ICSs delivery. 35, 36, 47, 70 In fact, at least for the currently marketed nebulized ICSs that are available as suspensions, the micronized drug is distributed mainly in particles larger than 2-3 m in diameter 36 (as shown in supplementary Appendix 1), so that droplets with a smaller size would contain mainly water and not drug.
Interestingly, all components of the nebulizer system are important in determining good lung delivery of ICSs (ie, the interface plays a very important role, largely modifying the IM and also influencing the MMAD). 58, 64 This was confirmed by an ex vivo study where the mean IM of nebulized BUD was 5-7% of the nominal dose inhaled through a face mask, while this percentage increased up to 9 -12% through a mouthpiece. 87 The same study showed that a good seal between the face and the mask approximately doubled the IM. 87 Another study with BUD has shown that the blow-by method of administration largely compromised the IM. 88 Thus, not only the nebulizer system, but even the modalities of inhalation widely influence the aerosol properties of nebulized ICSs. Barry and O'Callaghan 46 have demonstrated the role of the inhaling patient in an in vitro study, where they modified the inspiratory flow to resemble different breathing patterns and saw major differences in IM of nebulized BUD. In another ex vivo study, when 163 children ages 6 months to 7.9 years inhaled BUD through a Spira nebulizer, the IM ranged from 1.9% to 40.6% of the nebulizer load, according to the breathing modalities. 85 Manufacturers have tried to reduce the variability of performance related to the different breathing patterns of inhaling patients, leading, with advances in nebulizer technology, to the delivery of breath-enhanced and synchronized nebulizers.
As shown in the supplementary Appendix 3, some studies have found that BDP and FLU do not substantially differ from BUD regarding IM and droplet size distribution. 59, 66, 69 Less information is available for FP. Without any explanation of the method used, Westbroek et al 89 reported a respirable fraction of 12-16% of the initial FP charge for 3 commonly used nebulizer systems such as the SideStream/PortaNeb, the Pari LC Plus/Proneb Ultra and the Cirrus/PulmoAide. Importantly, not only the drug, but all other components of the liquid formulation have a relevant role for efficient drug delivery: increasing the fill volume from 2 mL to 7 mL improves the nebulizer efficiency up to 3-fold, but also increases the treatment time, while aerodynamic properties did not change. 90, 91 Mixing is another common practice when more medications are prescribed simultaneously. 20, [92] [93] [94] 
Pharmacokinetic and Scintigraphic Studies
It is agreed that a relevant amount of drug has to be delivered to the lung for effective aerosol treatment. Pharmacokinetics evaluates pulmonary bioavailability for a given drug. The pharmacokinetics of ICSs have been extensively reviewed. [102] [103] [104] [105] [106] Scintigraphic studies investigate lung drug delivery for a given aerosol. Because the dose released to the lower airways is nearly completely absorbed into the broncho-pulmonary circulation, the lung drug delivery roughly equals pulmonary bioavailability.
Regarding the nebulized ICSs, in healthy adults when 3 different nebulizers (Pari Inhalier Boy, Pari LC Plus, and Maxin MA-2) were used in a breath-synchronized manner, the systemic bioavailability of BUD was 13% of label claim and approximately 50 -70% of the IM. 107 In 10 asthmatic children ages 3-6 years who inhaled quietly through the mouthpiece of the Pari LC Plus/Master system, the systemic availability of BUD was 6.1% of label charge, corresponding to a quarter of the IM. 84 This result is in keeping with a scintigraphic study where the lung deposition of BUD in 2 children inhaling quietly with good seal of face mask via the Pari LC Plus/Proneb Ultra nebulizer was 5-8% of label claim. 108 The same study confirmed the key role of the inhaling subject for efficient drug lung delivery: 2 children, one whose mask was not sealed to the face, the other who was crying, showed a lung deposition of, respectively, 0.1% and 1% of initial charge. 108 Some pharmacokinetics studies have shown a substantial dose proportionality in both mean plasma and area under the curve levels when increasing doses of ICSs were nebulized. This result has been observed in 10 adult asthmatics who inhaled a daily dose of, respectively, 2 mg and 8 mg BUD, in a cross-over manner, with the Inhalier Boy. 109 Murphy et al 110 also obtained a similar finding when different doses of BUD (0.5 mg and 1 mg once daily, 1 mg and 2 mg twice a day) were administered to 120 moderateto-severe adult asthmatics with the Pari LC Plus/Master system through a mouthpiece. In the same study, in an attempt to compare a nebulizer with an inhaler, a 3-fold difference in potency was estimated, favoring the Turbuhaler dry powder inhaler. Using the Pari LC Plus/Master system with a mouthpiece, another single-dose study in 12 healthy adults observed a dose proportionality by nebulizing BDP 1.6 mg and 3.2 mg; in the same study the comparison with chlorofluorocarbon-propelled BDP via metered-dose inhaler (MDI) added to a valved holding chamber (VHC) suggested a 2-fold potency ratio between MDI and nebulizer, favoring the first device. 111 These results with marketed ICS formulations do not consider some recent advances in nebulizer technology: in 10 asthmatics (mean age 20 months) ages 6 -41 months, the mean lung deposition for a novel formulation of nebulized budesonide via an eFlow was 34% of nominal dose: a percentage similar to that of the most efficient inhalers. 42 
Pharmacodynamics
Pharmacodynamics evaluates the clinical value of a certain drug, using both efficacy and safety measures. Unfortunately, a full pharmacodynamic evaluation of nebulized ICSs is not available for several reasons. First, ICSs have anti-inflammatory activity, but the value of direct biomarkers of airway inflammation, such as exhaled nitric oxide or eosinophil cell count, needs to be fully established. So the most commonly used parameters to assess the efficacy of ICSs, such as the improvement in baseline lung function and symptom scores, the reduction of bronchitic exacerbations, and rescue ␤ agonists use, are indirect and relatively insensitive indices. It means that the dose-response effect is relatively flat, making it possible to detect differences only when the ICS is at least quadrupled over the baseline dose. [112] [113] [114] [115] [116] [117] [118] Second, the improvement (or worsening) in the control of asthma occurs within some days from starting (or stopping) treatment, but treatment is required for up to 4 -8 weeks 119, 120 or more 121 to reach the maximum effect. This complicates the interpretation of results from cross-over, step-down, or step-up titration studies. 122, 123 On the other hand, a full estimation of ICS potency requires parallel studies of long-term duration (at least 1 month of regular treatment) with a large sample size of subjects for a range of drug dosages and disease severity, studies not easily performed. 124 In Table 1 I have reported 16 randomized, blind, placebo-controlled studies with nebulized ICSs in patients with chronic persistent asthma and COPD. 6, 89, 113, [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] Three studies had a cross-over design; the remaining were parallel. Five studies, 125, 128, 133, 135, 136 including 187 subjects, used FLU at different daily doses up to 2 mg. Two studies, enrolling 192 subjects, used BDP at daily doses of 0.8 -4 mg. A study with FP at daily doses of 1-4 mg, included 301 adults with severe asthma. The clinical experience with BUD is the most extensive, for a total of 8 studies enrolling 1,258 asthmatic subjects, mostly pediatric (0.5-8 years of age). Compared to placebo, BUD significantly improved disease control for both subjects not previously receiving ICSs nor well controlled by bronchodilators, and for those on prior ICSs use. Efficacy was already demonstrated at a daily dose of 0.5 mg with once daily administration of BUD, although evidence supporting the efficacy of the twice daily and higher dosing is stronger.
Although ICSs have a better therapeutic ratio than systemic corticosteroids, when higher doses are administered, relevant absorption occurs, with the potential to give systemic adverse effects. Measurements of adrenal suppression are usually considered as the most sensitive marker for ICSs' systemic activity. In fact, exogenous corticosteroids can attenuate natural production of cortisol by a negative feedback on the hypothalamic-pituitary-adrenal axis. Safety data are available mainly for BUD. Ten adult asthmatics who inhaled an 8 mg daily dose of BUD via the Inhalier Boy system had morning cortisol levels lower than when they received a 2 mg daily dose. 109 However, these high dosages of BUD are seldom used in clinical practice. The effect of BUD at daily doses up to 2 mg on the hypothalamic-pituitary-adrenal axis was studied in 293 pediatric asthmatics, ages 6 months to 8 years, for up to 52 weeks, without any clinically important difference, as compared to the conventional treatment group (where 35% were using ICSs via inhalers). 138 On the whole, adrenal suppression seems to occur occasionally at the highest doses after long-term regular treatment periods, perhaps in susceptible individuals. 131, 139 Another major concern in pediatric age is the possibility of a negative effect of ICSs on body height. Again, the most information is available for BUD: a total of 670 pediatric asthmatics were randomized in a 2:1 ratio to receive BUD (titrated to the lowest clinically effective dose, with median total daily dose ranging from 0.5 to 1 mg) or conventional asthma therapy for 52 weeks, in a real life setting, 138 with no difference of growth between groups, even when stratified by sex and age. 140 A small but statistically significant difference in growth velocity (Ϫ0.8 cm/y, P ϭ .002) was observed only between the BUD group and that of conventional treatment where ICSs were not allowed. 131 Likewise, as more extensively shown for ICSs administered via MDIs, this result did not affect the final height to be achieved. [141] [142] [143] [144] Post-marketing surveillance data have confirmed the safety of nebulized ICSs across all ages. 145, 146 BUD and BDP have also been used safely in pregnant women. [147] [148] [149] [150] Importantly, despite the fact that substantial facial and eye deposition may occur using nebulizer with face mask, 151 local adverse events are not commonly reported. Skin related side effects have been observed only in 2% of children, with no reports of cataract. 152, 153 In Table 2 I have reported 18 comparative studies that included nebulized ICSs. 6, 82, [109] [110] 117, 139, [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] Five studies used inhalers as the benchmark against which the comparison has been set up. Three of these studies explored the clinical value of nebulized BDP. BDP administered via the Pari LC Plus/ProNeb Turbo demonstrated to be not less effective than the same drug delivered via inhalers at half dose in 301 asthmatics of different ages and disease severity. [158] [159] [160] The results of earlier studies with nebulized BDP were contrasting, [166] [167] [168] probably as a result of the low strength of the used preparation, impeding a sufficient lung drug delivery. 169 Another study showed that an 8 mg daily dose of BUD given to 10 adult asthmatics via an Inhalier Boy for 4 weeks was more effective than a 1.6 mg daily dose of budesonide delivered via MDI with VHC. 109 On the contrary, Murphy et al did not find any difference in efficacy and safety between different doses of BUD and budesonide given via the dry powder inhaler Turbuhaler at a daily dose of 0.4 mg twice a day. 110 Investigating the systemic activity of ICSs, Wales et al 170 did not observe any consequence after inhalation of a single 4 mg dose of BUD, while serum cortisol levels significantly decreased when the same volunteers inhaled either budesonide 4 mg using a Turbuhaler or 4 mg fluticasone propionate using Table 1 2 Indicates a significant decrease for a given outcome when the active group is compared to the placebo arm. 1 Indicates significant improvement for a given outcome when the active group is compared to the placebo arm. ‡ Crossover study design with no wash-out period. § All subjects were inhaled corticosteroid (ICS) dependent (at least 5 mg total daily dose of prednisolone or equivalent 
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* The studies have a parallel design unless otherwise specified. Ͼ indicates a significant difference between treatments. † When more dosages are applied, the result is intended as the same for all dosages unless otherwise specified. ‡ Not on prior inhaled corticosteroid (ICS) use. § Unstable moderate to severe asthma. With down titration. ¶ Moderate persistent asthma. ** Unstable moderate asthma despite prior stable ICSs use (0.4-1 mg daily of BDP or equivalent); crossover design, no wash-out period. No details for MDI use. † † 71% on prior stable ICS use of no more than 0.4 mg BDP or equivalent; oral prednisolone was given at a daily dosage of 2 mg/kg (maximum 40 mg) for 4 days, followed by 1 mg/kg (maximum 20 mg) for 3 days; crossover study design with a 2-4 week wash-out period. ‡ ‡ Indicates the primary outcome of the study. § § Moderate to severe persistent unstable asthma despite prior stable ICSs use at mean daily dosage of 0. an MDI with a VHC. Finally, in another study on 14 healthy adults in which the effect of a single 2 mg dose of FP on hypothalamic-pituitary-adrenal axis was compared to MDI added to VHC, the latter showed approximately a 7-fold higher suppressant effect, as compared to the nebulizer Pari LC Plus. 171 Overall, the problem of equivalence among different devices remains undefined. Other comparative studies have addressed the problem of individualizing (or adjusting) the lowest effective dose of nebulized ICS (mostly with BUD) to obtain asthma control, without any ultimate conclusion. The dose-response effect is not well defined with nebulized ICSs: only when the ICS dosage was increased 4-fold was a difference sometimes observed in terms of efficacy 117, 154 and safety. 109 Likewise, the dose-response trend was observed for some efficacy variables only in one 113 of the 3 seminal pediatric randomized double-blind placebo-controlled studies with BUD, 113, 130, 131 and not at all after patient stratification by age. 172 The results of placebo-controlled blinded studies evaluating the role of nebulized ICSs in acute settings are displayed in the supplementary Appendix 5. [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] These studies have been performed in either emergency rooms or in hospital. Although the active treatment group often shows some advantage in terms of efficacy with respect to the placebo arm, no firm conclusion can be drawn. Overall, the clinical importance of ICSs in acute settings is not well defined. At present, the use of an ICS at 4 times the maintenance dose is considered an alternative to systemic corticosteroids only for mild-to-moderate acute asthmatic episodes. 1 In more severe attacks, current guidelines recommend the early use of systemic corticosteroids, but do not include ICSs. 183 Unfortunately, systemic corticosteroids induce relevant adverse effects, even with short-term treatments. 184, 185 The results of blinded comparison studies evaluating the role of nebulized ICSs in acute settings are displayed in the supplementary Appendix 6. 173, [177] [178] 180, [186] [187] [188] [189] [190] [191] [192] [193] Ten of these 12 studies compared nebulized ICSs to systemic corticosteroids, which are the mainstay of anti-inflammatory treatment in exacerbations. Due to differences in methods and enrolled population, the results of different studies cannot be pooled, and firm conclusions cannot be obtained. The problem of equivalence between nebulized ICSs and systemic corticosteroids also remains undefined. A significant dose-related suppression was observed in adult asthmatics with oral prednisolone at daily doses ranging from 5 to 20 mg, but not with BUD given via a Ventstream/PortaNeb nebulizer system at daily dosages ranging from 1 to 4 mg for 4 days. 194 Moreover, ICSs could be not only safer than systemic corticosteroids, but also assure earlier results via nongenomic effects. [195] [196] [197] Possibly, the critical parameter for clinical efficacy, at least in asthmatics, might not be the total dose of ICSs, but rather the timings of delivery, with earlier repeated administrations (every 15-20 min for up to 2-4 h) giving greater benefits. 198 Finally, the value of ICSs for the treatment of asthmatic and COPD exacerbations is promising, 12, [198] [199] [200] [201] but not fully evidence-based and cannot be recommended. The confirmation of an important role for ICSs in acute settings would enlarge the use of nebulized ICSs, as many health caregivers prefer to administer aerosol therapy via nebulizers in the hospital 202 and in emergency departments. 203 Although most randomized placebo-controlled blinded studies have administered nebulized ICSs alone, 8 trials used co-admixtures of ICSs and bronchodilators. 136, 137, 173, 174, 176, 179, 181, 182 A study where FLU was mixed with bronchodilators and administered via the Nebula system was carried out in at least moderate COPD, with a trend of improved symptom score and reduced severe exacerbation rate. 136 The remaining studies were performed in asthmatics: 6 studies were performed in acute settings, mixing either BUD 173, 174, 176, 181, 192 or FP 179 with bronchodilators, via a variety of nebulizer systems. Four 173, 174, 176, 192 of these studies showed a significant result in terms of clinical efficacy when the co-admixture including the nebulized ICSs was compared to the placebo arm. The last study observed a significant improvement in symptom score and symptom free days in children with intermittent wheezing who received a co-admixture of BDP and albuterol via the Comp Air Elite system. 137 Although promising, the clinical effects of mixing nebulized ICSs with other nebulizable drugs needs confirmation to be recommended.
Discussion
Several large randomized controlled studies in subjects with chronic persistent asthma have demonstrated the efficacy and safety of BUD at daily doses from 0.5 mg to 1 mg, with a range of jet nebulizers (Aiolos, DeVilbiss 646, Hudson Up-draft, Pari Inhalier Boy, Pari LC Plus, and VentStream). In vitro and some in vivo comparative and placebo controlled studies suggest that nebulized BDP, FLU, and FP, with some differences among them, are also clinically effective and safe. Clear-cut indications about the recommended drug dosages are difficult, because a dose-response trend is inconsistently observed for nebulized ICSs. From a practical point of view, it means that, when the desired clinical effect is achieved, the total daily dose of the nebulized ICS must be individualized for each patient, with the goal of tapering to the lowest effective dose to maintain disease control and to avoid the risk of relevant systemic side effects.
Three main drawbacks have limited a larger use of nebulized ICSs. First, most trials on ICSs have used inhalers, so that they have stronger evidence in efficacy than nebulizers. Second, some nebulizer systems are not suitable for efficient lung delivery of ICSs. This observation is relevant, as nebulized drugs and nebulizers are sold separately and a lot of physicians are not familiar with the practice of nebulized ICSs. This raises concerns that the nebulization of ICSs is not always optimally performed. Effectively, in real life, a variety of nebulizer systems and operating modalities have been described for nebulizing ICSs, and many of these practices are not evidencebased. 20, 94, 204 Third, all currently marketed nebulized ICSs have a relatively poor lung delivery. Most inhalers have greater efficiency than nebulizers for delivering ICSs. Although bioequivalence in clinical outcome among different devices might be overcome by increasing the dosage of the nebulized ICS, it implies longer times of administration, a major determinant for poor adherence to treatment, 110 and higher costs. By estimating a 1:2 potency ratio between BUD and budesonide Turbuhaler 205 and equivalence between nebulized BUD, BDP, FLU, and FP, the cost (by Italian standards) for a 10-day course of treatment is approximately €5 for budesonide Turbuhaler at a daily dosage of 0.4 mg, versus €28 for BUD, €20 for FLU and FP, and €12 for BDP. However, the cost of nebulized ICSs is variable among countries. The United States price for a 10-day course of BUD at daily doses of 0.25, 0.5, and 1 mg is, respectively, $27, $42, and $68. 206 Thus, at present, nebulizers are a second choice, compared to hand-held inhalers, for delivering ICSs. Nebulized ICSs can be prescribed to patients who are unwilling or unable to use inhalers. However, this occurrence is common not only in infants, but even in the elderly, where, despite improvement in technology, inhaler misuse remains common in real life and is associated with poor disease control. 207 Accordingly, most adult patients who receive home nebulizer therapy are advanced in age and have many associated comorbid diseases, severe respiratory conditions, and common failure with other therapies. 20, 204, [208] [209] [210] Interestingly, in asthmatic children with a history of either hospitalization or emergency department visits for asthma, only the use of nebulized BUD has been associated with reduce risk of relapse. 211, 212 In addition, a decrease in systemic corticosteroid use and a trend of reduced emergency department visits and hospitalizations have been reported in elderly patients with chronic lung diseases regularly using nebulized ICSs. 210 Newer formulations of ICSs could probably improve the efficiency of nebulizers, possibly becoming equivalent to that of inhalers with the best lung drug deposition. 38, 39, [41] [42] [43] [44] Interestingly, newer ICSs with customized nebulizers can effectively deliver aerosols with MMADs smaller than 2-3 m, with the potential of improved lung delivery 211 and better clinical outcomes 212 to infants, a traditionally complicated group to treat with therapeutic aerosols. 213, 214 Summary I conclude that nebulized ICSs are currently a valid alternative to inhalers in asthma and COPD. Meaningful recommendations for good practice with nebulized ICSs should be implemented in clinical practice. Additional research is required to confirm the promising role of ICSs in acute settings and the possibility of mixing nebulized ICSs and bronchodilators. Other studies should clarify whether ongoing ICS formulations may offer clinically important advantages over the currently available nebulized ICSs.
